Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients [2]

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 3, 2002, Pages 364-366

  Tortajada, Cecilia ^a   Pérez Cuevas, Bernardo ^a   Moreno, Asuncion ^a   Martínez, Esteban ^a   Mallolas, Jose ^a   García, Felipe ^a   Valls, Eugenia ^a   Miró, José M ^a   De Lazzari, Esther ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MEGLUMINE ANTIMONATE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LETTER; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; RELAPSE; SPAIN; SURVIVAL RATE; VISCERAL LEISHMANIASIS;

EID: 0036640562     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200207010-00015     Document Type: Letter

References (9)

1. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
2. Declining incidence of visceral leishmaniasis in HIV-infected individuals in the era of highly active antiretroviral therapy
3. Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals
4. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: Report of two cases
5. Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: Failure of parasite eradication despite increase in CD4+ T-cell count but low CD8+ T-cell count
6. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy
7. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B
8. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
9. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection